What question did this study set out to answer?

Examine the advancements and evolution of anticoagulant therapy over the last century.

June 18, 2026Thrombosis ResearchOpen Access

Anticoagulation evolves from VKAs to DOACs as novel contact activation pathway agents enter development.

Q: What is the clinical evidence from this study?

Study design: Review. Population: thromboembolic disease. Intervention: Anticoagulant therapy.

View Full Paper

Ask AI

Bookmark

Design

Review

Key result

Anticoagulant therapy has evolved from vitamin K antagonists to direct oral anticoagulants, with novel agents targeting the contact activation pathway currently in development.

Authors

NCNoel C. Chan AIA Imiela SCStephanie Carlin

Discussion

Member takes

Overview

Does not alter current anticoagulant practice; leaves open whether Factor XI inhibitors can uncouple efficacy from bleeding risk.

Key Points

Examine the advancements and evolution of anticoagulant therapy over the last century.
Historical analysis of anticoagulant therapy from the 1940s to present.
Evaluation of the development and impact of VKAs, LMWH, and DOACs.
Discussion of ongoing phase III trials for novel anticoagulants targeting the contact activation pathway.
VKAs like warfarin became widely used after their discovery in the 1940s.
Introduction of weight-based dosing in LMWH enhanced outpatient anticoagulation safety and convenience.
DOACs simplified oral anticoagulation and are preferred over VKAs for many conditions, although novel anticoagulants may further improve safety by targeting specific coagulation pathways.

PICO

Population

thromboembolic disease

Intervention / Comparator

Anticoagulant therapy

This historical review outlines the progression of anticoagulant therapies and the potential of emerging Factor XI inhibitors to uncouple bleeding risk from antithrombotic efficacy.

Cite This Study

Chan et al. (2026) conducted a review in thromboembolic disease. Anticoagulant therapy was evaluated. Anticoagulant therapy has evolved from vitamin K antagonists to direct oral anticoagulants, with novel agents targeting the contact activation pathway currently in development.

synapsesocial.com/papers/6a33cfcf14a9c556e66778c3 https://doi.org/10.1016/j.thromres.2026.109753

View Full Paper

Ask AI

Bookmark

June 18, 2026Thrombosis ResearchOpen Access

Anticoagulation evolves from VKAs to DOACs as novel contact activation pathway agents enter development.

View Full Paper

Ask AI

Bookmark

Design

Review

Key result

Anticoagulant therapy has evolved from vitamin K antagonists to direct oral anticoagulants, with novel agents targeting the contact activation pathway currently in development.

Authors

NCNoel C. Chan AIA Imiela SCStephanie Carlin

Discussion

Member takes

Overview

Does not alter current anticoagulant practice; leaves open whether Factor XI inhibitors can uncouple efficacy from bleeding risk.

Key Points

Examine the advancements and evolution of anticoagulant therapy over the last century.
Historical analysis of anticoagulant therapy from the 1940s to present.
Evaluation of the development and impact of VKAs, LMWH, and DOACs.
Discussion of ongoing phase III trials for novel anticoagulants targeting the contact activation pathway.
VKAs like warfarin became widely used after their discovery in the 1940s.
Introduction of weight-based dosing in LMWH enhanced outpatient anticoagulation safety and convenience.
DOACs simplified oral anticoagulation and are preferred over VKAs for many conditions, although novel anticoagulants may further improve safety by targeting specific coagulation pathways.

PICO

Population

thromboembolic disease

Intervention / Comparator

Anticoagulant therapy

This historical review outlines the progression of anticoagulant therapies and the potential of emerging Factor XI inhibitors to uncouple bleeding risk from antithrombotic efficacy.

Cite This Study

synapsesocial.com/papers/6a33cfcf14a9c556e66778c3 https://doi.org/10.1016/j.thromres.2026.109753

View Full Paper

Ask AI

Bookmark